What is KPV?

A tripeptide, lysine–proline–valine (Lys-Pro-Val), that the FDA describes as a fragment of alpha-melanocyte-stimulating hormone (α-MSH), a pituitary neuropeptide.

At a glance

What it is
A tripeptide, lysine–proline–valine (Lys-Pro-Val), that the FDA describes as a fragment of alpha-melanocyte-stimulating hormone (α-MSH), a pituitary neuropeptide.
Also called
Lys-Pro-Val · lysine–proline–valine · KPV acetate · alpha-MSH(11-13)
US status
HHS discretionHHS says it does not intend to act against 503A compounding that meets its conditions. That is not an approval.
Evidence
F: None, or contradictedAll KPV evidence comes from cell or animal studies; we found no human study.
Safety signal
No data (unknown ≠ safe)Everyone. Pregnancy, breastfeeding, children, long-term use, every route.

Status checked Nov 16, 2026 · Draft policy

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Reviews0The FDA's 2026 review found no human data of any kind: no published study of KPV in people, compounded or not, no human PK study, no case report, and not "any clinical studies or human exposure data" by any route.6

Safety facts

Reports to the FDA

  • The FDA's own search of FAERS, through December 3, 2025, found 0 reports, and its complaint system (HFCS, 2004 to December 3, 2025) holds no case where KPV was given. FAERS data to October 28, 2026 also hold 0 reports of KPV.612

What the FDA has said

  • The FDA's Category 2 page says the FDA "has not identified any human exposure data" for KPV and lacks information on whether it "would cause harm".5
  • The FDA's briefing calls both forms "not well-characterized": there is no standard naming and no published impurity, aggregate or microbiological testing, and the nominator supplied no certificate of analysis.6
  • The FDA said there are not enough data to conclude that KPV does not carry immunogenicity or aggregation risks, and that peptides as short as 2 amino acids can aggregate.6

No data

  • The FDA found no nonclinical toxicity studies of topical KPV. We found no carcinogenicity, reproductive or liver data in any source we read.6
  • We found no human data, no FAERS report and no FDA statement about KPV and the liver.
  • We found no human study of how the body handles KPV (pharmacokinetics) by any route, and no published human half-life.6
  • There are no data for any group: not for pregnancy, breastfeeding, children or long-term use, and not for any route.6

Compounded KPV is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

The conditions of the HHS policy

The policy covers a compounded product only when all of its conditions are met.

  1. The peptide is on Appendix A of the HHS policy1Legal
  2. It matches the identity and routes in Appendix B (for KPV: acetate, on the skin or by mouth)1Legal
  3. The active ingredient comes from an FDA-registered (section 510) facility, with a certificate of analysis for each lot covering identity, purity, potency, endotoxins, heavy metals, microbes and impurities1Legal
  4. The original manufacturer is FDA-registered, follows CGMP, and its location is on the certificate of analysis1Legal
  5. The compounder reports products, serious adverse events and quality issues to MedWatch and the states, and the patient labeling explains how to report1Legal
  6. The label reads "This is a compounded drug product. Not for resale."1Legal
  7. It contains a single active ingredient from Appendix A1Legal
  8. A form taken by mouth has documentation of adequate oral bioavailability in people1Legal
  9. The only device is a syringe the FDA cleared through 510(k)1Legal
  10. It meets all other FD&C Act requirements, is made without insanitary conditions, and has a valid prescription for one patient1Legal

  1. 1.
  2. 2.
    Appendix B: Peptide Identities and JustificationsTier 1: regulator or registerHHSread Nov 16, 2026↩
  3. 3.
    Federal Register notice FR Doc 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registerFederal Registerread Nov 16, 2026↩
  4. 4.
    Docket HHS-OASH-2026-0496Tier 1: regulator or registerRegulations.govread Nov 16, 2026↩
  5. 5.
  6. 6.
  7. 7.
    PCAC questions, July 23–24, 2026Tier 1: regulator or registerFDAread Nov 16, 2026↩
  8. 8.
    PCAC meeting page, July 23–24, 2026 (no minutes)Tier 1: regulator or registerFDAread Nov 16, 2026↩
  9. 9.
    Bulk-list bound? PCAC backs majority of peptides (Jul 27, 2026)Tier 3: reference, law firm or pressMcDermott Will & Schulteread Nov 16, 2026↩
  10. 10.
    WADA Prohibited List 2026Tier 1: regulator or registerWADAread Nov 16, 2026↩
  11. 11.
    USADA sanctions tableTier 1: regulator or registerUSADAread Nov 16, 2026↩
  12. 12.
    openFDA FAERS, medicinalproduct KPV (0; data to 2026-10-28)Tier 1: regulator or registeropenFDAread Nov 16, 2026↩
  13. 13.
    openFDA Drugs@FDA, active ingredient KPV (no match)Tier 1: regulator or registeropenFDAread Nov 16, 2026↩
  14. 14.
    eCFR 21 CFR Part 1308 (2026-11-01)Tier 1: regulator or registerOffice of the Federal Registerread Nov 16, 2026↩
  15. 15.
    ClinicalTrials.gov API, query.intr=KPV (0 studies)Tier 1: regulator or registerNIH NLMread Nov 16, 2026
  16. 16.
    PubMed E-utilities counts for KPV (queries in 3)Tier 1: regulator or registerNIH NLMread Nov 16, 2026
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
    Compounding and the FDA: questions and answersTier 1: regulator or registerFDAread Nov 16, 2026
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.